Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

NCT00686699 | Terminated Phase 2 Results

• 3 other identifiers: P046282005-006048-42MK-3814-014
• Study Type: interventional
• Target: 11
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder. Participants were to be evaluated for two 14-day treatment periods with a 3-week washout period between treatment periods. The primary outcome measure, Extrapyramidal Symptom Rating Score (ESRS), was to be evaluated frequently during the treatment periods.

Conditions

Akathisia, Drug-Induced; Dyskinesia, Drug-Induced; Parkinsonian Disorders

Keywords

Anti-Dyskinesia Agents; Antipsychotic Agents

Outcome Measures

Primary Outcomes (1)

• Lowest Extrapyramidal Symptom Rating Score (ESRS) Total Score Within the 6-hour Evaluation on Day 14 of Each Treatment Period

  The ESRS total score consists of 4 subscales: 1) a questionnaire of extrapyramidal symptoms (EPS) and drug-induced movement disorders (DIMD) over the previous 7 days (7 items scored as 0=Absent to 3=Severe; score range: 0-21), 2) an examination of Parkinsonism and akathisia (17 items scored as 0=None to 6=Severe; score range: 0-102), 3) an examination of dystonia (10 items scored as 0=Absent to 6=Most Severe; score range 0-60) and 4) an examination of dyskinesia (7 items scored as 0=None to 6=Severe; score range: 0-42). The ESRS total score could range from 0 to 225, with a lower score reflecting a better outcome. The lowest ESRS total score for each participant within the 6-hour range on Day 14 was analyzed.

  Up to 6 hours post-dose on Day 14

Secondary Outcomes (9)

• Mean ESRS Total Scores Within the 6-hour Evaluation on Day 14 of Each Treatment Period

  1, 2, 3, 4, 5, and 6 hours post-dose on Day 14

• Lowest ESRS Part I Subscore: EPS and DIMD Within the 6-hour Evaluation on Day 14 of Each Treatment Period

  Up to 6 hours post-dose on Day 14

• Mean ESRS Part I Subscore: EPS and DIMD Within the 6-hour Evaluation on Day 14 of Each Treatment Period

  1, 2, 3, 4, 5, and 6 hours post-dose on Day 14

• Lowest ESRS Part II Subscore: Parkinsonism and Akathisia Within the 6-hour Evaluation on Day 14 of Each Treatment Period

  Up to 6 hours post-dose on Day 14

• Mean ESRS Part II Subscores: Parkinsonism and Akathisia Within the 6-hour Evaluation on Day 14 of Each Treatment Period

  1, 2, 3, 4, 5, and 6 hours post-dose on Day 14

Study Arms (2)

Preladenant 25 mg BID→Placebo BID

EXPERIMENTAL

Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.

Drug: Preladenant

Placebo BID→Preladenant 25 mg BID

PLACEBO COMPARATOR

Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.

Drug: Placebo

Interventions

Preladenant DRUG

capsules

Also known as: SCH 420814, MK-3814

Preladenant 25 mg BID→Placebo BID

Placebo DRUG

capsules

Placebo BID→Preladenant 25 mg BID

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females \>=18 and \<=65 years old with a body mass index of 17-31 kg/m\^2.
• Diagnosed with Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV) criteria for schizophrenia/schizoaffective (depressive type) disorder with antipsychotic-induced extrapyramidal symptoms (parkinsonism, akathisia, dystonia, or tardive dyskinesia \[TD\]) based on the following ESRS criteria:
• parkinsonism, dystonia, or TD - ESRS score \>=2 on 2 items or \>=3 on one item,
• akathisia - ESRS score \>=3 on two items,
• Has total ESRS score \>8.
• Must be receiving neuroleptics at a stable dosage for at least 7 days prior to enrollment.
• Clinical laboratory tests, physical exam, and electrocardiogram must be within normal limits or clinically acceptable to the investigator/sponsor (except signs and symptoms of Schizophrenia/Schizoaffective disorder).
• Liver function tests must be within normal limits at screening.
• Participant screening for drugs with a high potential for abuse must be negative.
• Must be free of any clinically significant disease other than schizophrenia/schizoaffective disorder that would interfere with the study evaluations or procedures.
• Must have a level of understanding sufficient to communicate with research staff, cooperate with all protocol required tests and examinations, and be able to adhere to protocol restrictions and schedules.
• Must be able to understand the nature of the study and must be willing to sign an informed consent (required for each patient or the patient's authorized legal representative) prior to study enrollment.
• Females must have a follicle stimulating hormone (FSH) \>=40 lU/L and be greater than 12 months since last menses or surgically sterilized.

You may not qualify if:

• Has a history of clinically significant local or systemic infectious disease within 4 weeks prior to initial treatment administration, clinically significant food or drug allergy, seizures, alcohol/drug dependence, previous neurosurgery, or coronary artery disease (including myocardial infarction \[MI\], cerebrovascular disease \[stroke, transient ischemic attack (TIA)\], or peripheral arterial disease).
• Has participated in a clinical trial of an investigational drug within 60 days or donated blood within the preceding 90 days prior to the start of the study.
• Has circulating human immunodeficiency virus (HIV), hepatitis C antibodies, or hepatitis B surface antigen.
• Is allergic to preladenant (SCH 420814, MK-3814) or any excipients in preladenant capsules (citric acid, lactose monohydrate, croscarmellose sodium, magnesium stearate \[nonbovine, vegetable grade\], Food, Drug, and Cosmetic \[FD\&C\] blue, titanium dioxide, gelatin-national formulary \[NF\]).
• Females who are not surgically sterilized or postmenopausal.
• Males who are sexually active and who do not agree to use a barrier method of birth control during the study.
• Has severe/uncontrolled hypertension. (Participants with hypertension well controlled on a stable dose of standard anti-hypertensive medication for at least 4 weeks before randomization are eligible.)
• Has atrioventricular (AV) block, sick sinus syndrome, congestive heart failure, or participants with electrocardiograms (ECGs) consistent with ischemic heart disease, or significant Q waves.
• Has DSM-IV criteria of dementia (except due to schizophrenia/and schizoaffective disorder), or individuals who in the opinion of the investigator are not able to understand or comply with the study procedures or the instructions of the staff or are socially incapable to participate in the study.
• Does not comply with the requirement that participants should not use any drugs (except acetaminophen and other allowed medications) within 2 weeks prior to the study, nor alcohol (wine, beer) within 72 hours prior to drug administration.
• Judged clinically to be at suicidal risk too serious to be included in this study.
• Has received electroconvulsive therapy within 30 days before randomization.
• Is currently taking clozapine.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

MeSH Terms

Conditions

Akathisia, Drug-Induced; Dyskinesia, Drug-Induced; Parkinsonian Disorders

Interventions

2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine

Condition Hierarchy (Ancestors)

Movement Disorders; Central Nervous System Diseases; Nervous System Diseases; Neurotoxicity Syndromes; Psychomotor Agitation; Dyskinesias; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Drug-Related Side Effects and Adverse Reactions; Chemically-Induced Disorders; Poisoning; Basal Ganglia Diseases; Brain Diseases

Limitations and Caveats

This study was terminated due to low enrollment.

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2008
• First Posted: May 30, 2008
• Study Start: July 10, 2006
• Primary Completion: March 6, 2008
• Study Completion: March 6, 2008
• Last Updated: November 9, 2018
• Results First Posted: December 7, 2016

Record last verified: 2018-10

Data Sharing

• IPD Sharing: Will share